臨床泌尿器科68巻13号

2014年12月発行

特集 新時代を迎えたPET診断

原発不明癌におけるPET診断

著者： 高橋俊二¹

所属機関： ¹がん研有明病院化学療法部

ページ範囲：P.1040 - P.1045

文献概要

要旨　原発不明癌におけるPET，PET/CTの意義についてはかなりの報告があるが，ほとんどがretrospective studyである。頭頸部の原発不明癌では唯一の多施設前向き試験において通常の検索に加えてPET併用により29％の症例において原発病変が発見された。その他の原発不明癌ではPET/CTを追加することによる原発同定は30〜40％と高い確率が報告されているが，prospective studyがなく，確立しているわけではないため，ガイドラインでもはっきりとは推奨されていない。しかし，原発が明らかな疾患より見つけにくい転移巣を発見できる可能性も含めて，コストベネフィットは十分あると考えられる。

参考文献

1）Pavlidis N, Briasoulis E, Hainsworth J, et al：Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer 39：1990-2005, 2003

2）Pavlidis N and Fizazi K：Carcinoma of unknown primary（CUP）. Crit Rev Oncol Hematol 69：271-278, 2009

3）NCCA Practice Guideline in oncology occult primary v. 1 2014　http://www.nccn.org/professionals/physician_gls/f_guidelines.asp-occult

4）Oien KA：Pathologic evaluation of unknown primary cancer. Semin Oncol 36：8-37, 2009

5）Hainsworth JD and Fizazi K：Treatment for patients with unknown primary cancer and favorable prognostic factors. Semin Oncol 36：44-51, 2009

6）Greco FA and Hainsworth JD：One-hour paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of carcinoma of unknown primary site. Semin Oncol 24：S19-101-S19-105, 1997

7）Hainsworth JD, Burris HA, Calvert SW, et al：Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site：a phase Ⅱ trial of the Minnie Pearl Cancer Research Network. Cancer Invest 19：335-359, 2001

8）Hainsworth JD, Spigel DR and Raefsky EL, et al：Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site：a Minnie Pearl Cancer Research Network Phase Ⅱ trial. Cancer 104：1992-1997, 2005

9）Rusthoven KE, Koshy M, Paulino AC：The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101：2641-2649, 2004

10）Chen KT, Papavasiliou P, Edwards K, et al：A better prognosis for Merkel cell carcinoma of unknown primary origin. Am J Surg 206：752-757, 2013

11）Johansen J, Buus S, Loft A, et al：Prospective study of 18FDG-PET in the detection and management of patients with lymph node metastases to the neck from an unknown primary tumor. Results from the DAHANCA-13 study. Head Neck 30：471-478, 2008

12）Keller F, Psychogios G, Linke R, et al：Carcinoma of unknown primary in the head and neck：comparison between positron emission tomography（PET）and PET/CT. Head Neck 33：1569-1575, 2011

13）Smith KA, Dort JC, Hall SF, et al：Cost-effectiveness of positron emission tomography-CT in the evaluation of cancer of unknown primary of the head and neck. Head Neck, 2014

14）Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, et al：Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors. J Nucl Med 44：1301-1314, 2003

15）Kwee TC, Kwee RM：Combined FDG-PET/CT for the detection of unknown primary tumors：systematic review and meta-analysis. Eur Radiol 19：731-744, 2009

16）Moller AK, Loft A, Berthelsen AK, et al：18F-FDG PET/CT as a diagnostic tool in patients with extracervical carcinoma of unknown primary site：a literature review. Oncologist 16：445-451, 2011

17）Park JS, Yim JJ, Kang WJ, et al：Detection of primary sites in unknown primary tumors using FDG-PET or FDG-PET/CT. BMC Res Notes 4：56, 2011

18）Fizazi K, Greco FA, Pavlidis N, et al：Cancers of unknown primary site：ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22（Suppl 6）：vi64-68, 2011

19）日本臨床腫瘍学会：原発不明がん診療ガイドライン2010年版　http://www.jsmo.or.jp/about/kanko.html

20）Seve P, Billotey C, Broussolle C, et al：The role of 2-deoxy-2-［F-18］fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer 109：292-299, 2007